Literature DB >> 21091147

Acute erythroleukemia: diagnosis and management.

Fabio P S Santos1, Carlos E Bueso-Ramos, Farhad Ravandi.   

Abstract

Acute erythroleukemia is a rare subtype of acute myeloid leukemia that has undergone several changes in classification over the past 30 years. There are two subtypes of acute erythroleukemia: the more common erythroid/myeloid subtype, defined by the presence of increased erythroid cells and myeloid blasts; and the rarer, pure erythroid subtype, characterized by expansion of immature erythroid cells only. The erythroid/myeloid subtype of acute erythroleukemia is closely related to acute myeloid leukemia with myelodysplasia-related changes, and is frequently characterized by morphological dysplasia and complex karyotype. Pure erythroleukemia is a very uncommon subtype of leukemia associated with a very poor response and survival to current available therapeutic agents. Treatment results for this disease are suboptimal and new drugs are needed. This article summarizes current knowledge in the field of acute erythroleukemia.

Entities:  

Mesh:

Year:  2010        PMID: 21091147     DOI: 10.1586/ehm.10.62

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  14 in total

1.  Acute myeloid leukemia with expanded erythropoiesis.

Authors:  Anna Porwit; James W Vardiman
Journal:  Haematologica       Date:  2011-09       Impact factor: 9.941

2.  Molecular evidence of JAK2 p.V617F mutated pure erythroid leukemia arising from polycythemia vera.

Authors:  Alisha D Ware; Jacqueline Birkness; Amy S Duffield; Christopher D Gocke
Journal:  Virchows Arch       Date:  2018-04-02       Impact factor: 4.064

3.  Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines.

Authors:  Joana Jorge; Sara Petronilho; Raquel Alves; Margarida Coucelo; Ana Cristina Gonçalves; José Manuel Nascimento Costa; Ana Bela Sarmento-Ribeiro
Journal:  Invest New Drugs       Date:  2019-05-31       Impact factor: 3.850

4.  A rare de novo pure erythroid leukemia with JAK2 R683S mutation.

Authors:  Rebecca Z Xu; Aly Karsan; Zhaodong Xu; Brian R Berry
Journal:  Ann Hematol       Date:  2021-09-04       Impact factor: 3.673

5.  Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia.

Authors:  Jian Zhong Tang; Catherine L Carmichael; Wei Shi; Donald Metcalf; Ashley P Ng; Craig D Hyland; Nancy A Jenkins; Neal G Copeland; Viive M Howell; Zhizhuang Joe Zhao; Gordon K Smyth; Benjamin T Kile; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

6.  Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.

Authors:  Nicolas Waespe; Machiel Van Den Akker; Robert J Klaassen; Lani Lieberman; Meredith S Irwin; Salah S Ali; Mohamed Abdelhaleem; Bozana Zlateska; Mira Liebman; Michaela Cada; Tal Schechter; Yigal Dror
Journal:  Haematologica       Date:  2016-08-18       Impact factor: 9.941

7.  Treatment of acute erythroleukemia with Azacitidine: A case series.

Authors:  Francesca Pierdomenico; Antonio Almeida
Journal:  Leuk Res Rep       Date:  2013-06-07

8.  Modeling and targeting of erythroleukemia by hematopoietic genome editing.

Authors:  Ilaria Iacobucci; Chunxu Qu; Elena Varotto; Laura J Janke; Xu Yang; Aman Seth; Anang Shelat; Jake D Friske; Reiji Fukano; Jiyang Yu; Burgess B Freeman; James A Kennedy; Adam S Sperling; Rena Zheng; Yingzhe Wang; Harini Jogiraju; Kirsten M Dickerson; Debbie Payne-Turner; Sarah M Morris; Emily S Hollis; Nina Ghosn; Georgia E Haggard; R Coleman Lindsley; Benjamin L Ebert; Charles G Mullighan
Journal:  Blood       Date:  2021-03-25       Impact factor: 25.476

9.  A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia.

Authors:  E M Braunstein; R Li; N Sobreira; B Marosy; K Hetrick; K Doheny; C D Gocke; D Valle; R A Brodsky; L Cheng
Journal:  Leukemia       Date:  2016-06-15       Impact factor: 11.528

10.  Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML.

Authors:  Zhuang Zuo; L Jeffrey Medeiros; Zhao Chen; Dingsheng Liu; Carlos E Bueso-Ramos; Rajyalakshmi Luthra; Sa A Wang
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.